IP Library Granted Patent US 7,378,056
Granted Patent B2
US 7,378,056 · App. 10/005,889 · Granted May 27, 2008

Circuits for in vivo detection of biomolecule concentrations using fluorescent tags

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,378,056
App. No.
10/005,889
Granted
May 27, 2008
Kind
B2
Abstract

Methods are disclosed wherein labeled antibodies can be provided in vivo to tissue having antigens that specifically bind the labeled antibody. A first optical radiation is emitted into the tissue in vivo to excite the labeled antibody bound to the antigen in vivo. A second optical radiation that is emitted by the excited labeled antibody, in response to the excitation thereof, can be detected in vivo. Related telemetric circuits and compositions of matter are also disclosed.

Claims (26)

1. A circuit for detecting biomolecules in vivo, the circuit comprising

an optical radiation source configured for in vivo use that emits first optical radiation;

an optical radiation detector configured for in vivo use that detects second optical radiation emitted by excited labeled binding molecules; and

a processor circuit, coupled to the optical radiation source and the optical radiation detector,

wherein the processor circuit is configured to release fluorescently labeled antibodies selected to bind with predetermined Tumor Specific Antigens (TSAs),

the processor circuit is further configured to activate the in vivo optical radiation source after a predetermined first time interval after release of the fluorescently labeled antibodies, the predetermined first time interval selected to allow a first portion of the fluorescently labeled antibodies to bind with local available TSAs and a second portion of the fluorescently labeled antibodies to become remote from the circuit so that the first optical radiation excites the first portion of the fluorescently labeled antibodies bound with the local available TSAs and does not excite the second portion of the fluorescently labeled antibodies that become remote,

the processor circuit is further configured to sense a voltage generated by the in vivo optical radiation detector after a second predetermined time interval, the second predetermined time interval being after emission of the first optical radiation has ceased.

2. A circuit according to claim 1 , wherein the optical radiation source comprises a laser.

3. A circuit according to claim 1 , wherein the optical radiation detector is selected from a group consisting of a phototransistor, a photodiode, and a photomultiplier.

4. A circuit according to claim 1 , wherein the first optical radiation has a first frequency and the second optical radiation has a second frequency.

5. A circuit according to claim 4 , wherein the first frequency is greater than the second frequency.

6. A circuit according to claim 1 further comprising:

an emission filter coupled to the optical radiation source; and

an absorption filter coupled to the optical radiation detector.

7. A circuit according to claim 1 , further comprising:

an inductor coupled to the processor, wherein the inductor provides power to the circuit in response to a power signal received from the ex vivo system.

8. A circuit according to claim 1 , wherein the circuit is on a platform having a diameter of about 2 mm.

9. A circuit according to claim 1 , wherein the signal is digitally encoded.

10. A circuit according to claim 1 , wherein the circuit is on a platform coated with a biocompatible optical translucent layer.

11. A circuit according to claim 1 wherein the first and second optical radiation comprises first and second optical radiation at respective first and second wavelengths selected to promote transmission of the first and second optical radiation through a bio-fouling tissue on the optical radiation source and the optical radiation detector.

12. A circuit according to claim 1 wherein the circuit comprises an implantable circuit configured for in vivo implantation for at least six months.

13. A circuit according to claim 1 wherein the processor circuit is further configured to provide the signal for wireless transmission to the ex vivo system.

14. A circuit according to claim 1 further comprising:

a piezoelectric circuit responsive to the processor circuit, wherein the piezoelectric circuit is configured to vibrate under control of the processor circuit to release the labeled binding molecules.

15. A circuit according to claim 1 , wherein the processor circuit is further configured to control release of unlabled binding antibodies separate from the fluorescently labeled antibodies.

16. A circuit according to claim 15 wherein the processor circuit is further configured to release the unlabled binding antibodies during a first time interval and to release the fluorescently labeled antibodies during a second time interval.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 15, 2017
From: VTQ IP HOLDING CORPORATION
To: SNC HOLDINGS CORP. D/B/A SYNRYC HOLDINGS
Reel/Frame 044898/0838 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2013
From: SNC HOLDINGS CORP.
To: VTQ IP HOLDING CORPORATION
Reel/Frame 029719/0696 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2011
From: SICEL TECHNOLOGIES, INC.
To: SNC HOLDINGS CORP.
Reel/Frame 027370/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2002
From: BLACK, ROBERT D.
To: SICEL TECHNOLOGIES, INC.
Reel/Frame 012723/0085 →